BioSpace News Archive

Curebase, a company committed to democratizing access to clinical studies, and Portamedic, which provides mobile examination and mobile phlebotomy services in all 50 states and Puerto Rico, have announced an ongoing partnership in which Portamedic will collect blood samples and other tests from participating decentralized clinical trial patients’ homes throughout the U.S.

Pieces, a healthcare AI company, has been chosen as the technology partner for NRG Oncology’s FORTE study to accelerate the identification of participants eligible for a major clinical trial.

Daiichi Sankyo (TSE: 4568) and Sarah Cannon Research Institute (Sarah Cannon) announced that initial results from the first-in-human phase 1 study of DS-6000, a CDH6 directed DXd antibody drug conjugate (ADC), suggest early clinical activity in patients with advanced ovarian cancer or renal cell carcinoma with disease progression following standard of care treatment.

NuGen Medical Devices Inc. is pleased to announce the launch of a new online brand store for its InsuJet TM needle-free injection device.

Palisade Bio (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that Tom Hallam, Ph.D., Chief Executive Officer of Palisade Bio, will present on Monday, June 13, 2022 at 1:45 PM PT at the 2022 BIO International Convention being held in San Diego, CA.

Phase 2 Dose‑Ranging Clinical Trial Results of CTP‑543 in Patients with Alopecia Areata published in the Journal of the American Academy of Dermatology .

Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, today announced a collaboration with Novo Nordisk, a leading global healthcare company, to create novel expression hosts for pharmaceutical products.

MetasTx LLC is driven to create novel therapeutics to treat and prevent metastasis of cancers.

Brooklyn ImmunoTherapeutics, Inc . (Nasdaq:BTX) (“Brooklyn” or the “Company”), a biopharmaceutical company focused on exploring the role that cytokine, gene editing, and cell therapy can have on the immune system for treating patients with cancer, blood disorders, and monogenic diseases, today announced the following appointments to the Board, effective June 5, 2022.

CEL-SCI Corporation (NYSE American: CVM) today announced that its abstract and poster titled “Leukocyte interleukin injection (LI) immunotherapy extends overall survival (OS) in treatment-naive low-risk (LR) locally advanced primary squamous cell carcinoma of the head and neck.